Drug Approval | October 20, 2021
FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Second interchangeable biosimilar product approved by agency
Second interchangeable biosimilar product approved by agency
It is the first presbyopia-correcting lens implant for cataract surgery
The company is eligible for 180 days of generic drug exclusivity for Lenalidomide capsules, 2.5 mg and 20 mg
The company claims that its Empagliflozin tablets are the most affordable in India
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
The capsules are indicated for the maintenance of normal sinus rhythm in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
Subscribe To Our Newsletter & Stay Updated
